- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. C16021Publication without faculty affiliation
- Research Report University Hospital for clinical assessment C16010Publication without faculty affiliation
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma2018 | First Faculty of Medicine
- Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial2020 | First Faculty of Medicine
- The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products2023 | Faculty of Pharmacy in Hradec Králové
- Proteasome inhibitors in the treatment of multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma2018 | First Faculty of Medicine
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial2019 | Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial2020 | First Faculty of Medicine
- Novinky v léčbě mnohočetného myelomu v roce 20172018 | First Faculty of Medicine
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma2018 | First Faculty of Medicine
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial2022 | First Faculty of Medicine
- Multiple myeloma - are we in 2020 able to cure the patient?2020 | First Faculty of Medicine
- Renal failure in multiple myeloma and its treatment2020 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: C16010Publication without faculty affiliation
- MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials2023 | First Faculty of Medicine
- AL amyloidosis: advances in diagnostics and treatment2019 | First Faculty of Medicine